Together, this study not only shown that the carcinogenic potential of PSMD14 in osteosarcoma but also investigated the potential molecular pathways by which the pathway PSMD14 contributes to OS progression and found that PSMD14 could encourage anlotinib resistance in osteosarcoma sublines that are already resistant to the drug. This evidence concerns the gene PSMD14 and osteosarcoma.